Assessing the Risk of Pulmonary Embolism in Patients After Hospitalization for First Episode of Syncope

NCT ID: NCT03034525

Last Updated: 2017-01-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 7000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-02-01
• Study Completion Date: 2018-02-01

Brief Summary

Acute pulmonary embolism (APE) is a common disease, which involves significant morbidity and mortality. The clinical presentation of APE has many faces but it is acceptable to suspect this disease when the patient presenting with at least one of the following: shortness of breath, pleuritic chest pain, cough, sub-febrile fever or hemoptysis.

The relationship between syncope and APE is not entirely clear. Prandoni et al conducted a systematic process for the exclusion / confirmation of APE all patients hospitalized for a first investigation of syncope. In this study APE was diagnosed in about 17% of the patients. In 12.7% of patients with an alternative explanation for syncope APE was diagnosed. Interestingly, 25% of the patients had no other manifestation of pulmonary embolism apart from the syncope itself.

According to the updated clinical guidelines, APE should not be routinely tested as an etiology for syncope and not systematically excluded. According to the new data presented by Prandoni et al, this means that a significant percentage of patients hospitalized for an investigation of syncope are discharged when they are suffering from APE (in most cases probably an event of unprovoked pulmonary embolism) without treatment with anticoagulants, making them particularly prone to PE recurrence.

Aim. To examine the incidence of pulmonary embolism (Pulmonary Embolism, PE), and VTE (venous thromboembolism, VTE) in patients hospitalized for a first investigation of syncope.

Detailed Description

Method.

Study population:

The study is a retrospective, multicenter cohort study, conducted at Rambam Health Care Campus and Sourasky Medical Center, Tel Aviv and includes all Clalit HMO insured patients who were admitted for investigation of first event of syncope from 2006 to 2013 (diagnosis on admission- syncope and collapse (ICD9 code 427.31)).

Inclusion criteria:

• Patients over 18 years old during study period.
• On admission diagnosis of syncope and collapse (ICD9 code 427.31).
• Patients are insured by Clalit Health Services.

Exclusion criteria:

• Hospitalization during the study period for additional event of syncope.
• Patients receiving anticoagulation on recruitment.
• Patients investigated for APE during hospitalization (by testing for D-dimer, computerized tomography angiography or perfusion-ventilation lung scan).
• Patients who began treatment anticoagulation, not because of VTE, during study period.

Study design The research is divided into two main stages. At the first phase data of the relevant study population will be collected from the computerized medical record of the two medical centers mentioned above and according to the inclusion and exclusions criteria listed above.

In the second phase we will examine in the study population the occurrence of PE or DVT within 36 months from hospitalization.

Conditions

Pulmonary Embolism; Syncope

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patients over 18 years old during study period.

• On admission diagnosis of syncope and collapse (ICD9 code 427.31).
• Patients are insured by Clalit Health Services.

Exclusion Criteria

• Hospitalization during the study period for additional event of syncope.

• Patients receiving anticoagulation on recruitment.
• Patients investigated for APE during hospitalization (by testing for D-dimer, computerized tomography angiography or perfusion-ventilation lung scan).
• Patients who began treatment anticoagulation, not because of VTE, during study period.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rambam Health Care Campus

OTHER

Sponsor Role: lead

Responsible Party

rambam71

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

551-16-CTIL

Identifier Type: -

Identifier Source: org_study_id